Streetbeat News

Regulatory

TRAW

Traws Pharma announced positive Phase 1 results for its investigational flu therapy, Tivoxavir Marboxil, showing good tolerability and effective plasma drug levels. The company plans to advance to Phase 2 trials in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:40 am

ZENA

ZenaTech, Inc. (NASDAQ:ZENA) has launched commercial drone services in the US through its subsidiary, ZenaDrone, after receiving FAA approval. The company will offer Drone-as-a-Service (DaaS) operations for agriculture and industry, initially from Phoenix, Arizona. ZenaDrone is also seeking an aerial spraying license for agricultural applications.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:37 am

VVOS

Vivos Therapeutics has received approval from the American Medical Association for new CPT medical codes for its Vivos CARE oral devices, effective January 1, 2025. This approval is expected to enhance insurance coverage and accessibility for their sleep apnea treatments, potentially driving revenue growth.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:35 am

CLF

The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Cleveland-Cliffs' acquisition of Stelco has expired, clearing a regulatory hurdle. The sale is expected to close in Q4 2024 after other conditions are met.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:18 am

GSK

GSK announced new data from its AReSVi-006 Phase 3 trial for the Arexvy RSV vaccine, showing efficacy and safety over three seasons in adults aged 60 and older. The data supports the vaccine's use, especially for those at increased risk, and GSK will continue to provide long-term follow-up data.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:14 am

TNXP

Tonix Pharmaceuticals has secured a $34 million contract from the U.S. Department of Defense to advance its TNX-4200 antiviral program. The company is collaborating with X-Chem to use AI and ML in developing oral antivirals. This partnership aims to optimize drug candidates' properties and accelerate development.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:12 am

TRAK

ReposiTrak has expanded its traceability network to include 4,000 suppliers, aiding retailers and wholesalers in preparing for FSMA 204 compliance. This expansion indicates that many suppliers are already traceability-ready.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:07 am

TEVA

Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted and the European Medicines Agency has validated applications for TVB-009P, a biosimilar candidate to Prolia. Decisions from both agencies are expected in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:01 am

GRDI

Griid Infrastructure has received a non-compliance notice from Nasdaq, which could impact its stock listing status. This notice is a significant development for the company and its investors.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 10:07 am

CDNA

CareDx announced that the DOJ has concluded its investigation with no findings of wrongdoing and will not take further action. This follows the SEC's decision to close its investigation without action. CareDx plans to defend itself if a former employee proceeds with litigation.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 10:07 am